Latest From Foghorn Therapeutics
Previewing the year to come, our journalists contacted more than 80 industry executives and experts for their views on what 2020 could hold for the biopharma sector. A series of articles based on these discussions were published by In Vivo’s sister publication Scrip. The following are highlights of the key issues that are top of mind for industry leaders this year, including digital tools, advanced therapies, the US election and manufacturing.
From the general to the particular: drug developers are increasingly tailoring therapies to individuals. Driven by important advances in understanding biology as well as new tools to harness big data, industry participants expect significant progress in biopharma’s approach to the patient.
Private Company Edition: The VC firm and start-up factory Flagship Pioneering brings in new cash for existing investments, tapping into investors eager to back "big, bold platform ideas" in the life sciences. Also, new financings include $100m-plus deals for Harmony and Beam.
China's JW Therapeutics nets $90m for cancer cell therapy, including backing from biotechs Celgene and WuXi. Meanwhile, Foghorn sounds out a $50m A round for its gene trafficking technology applications.
- Therapeutic Areas
- Immune Disorders
- Neurology, Nervous System
- North America
- Company Type
- Parent & Subsidiaries
- Foghorn Therapeutics
- Senior Management
Adrian Gottschalk, Pres. & CEO
Allan Reine, MD, CFO
Steve Bellon, MD, VP, Drug Discovery
Carl P Decicco, PhD, CSO
Samuel Agresta, MD, CMO
- Contact Info
100 Binney St.
Cambridge, MA 02142
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.